NLSP NLS Pharmaceutics Ltd

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of June 2023

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

Attached hereto and incorporated by reference herein is the Registrant’s Notice of Meeting and Proxy Card for the Ordinary Shareholders’ Meeting to be held on June 30, 2023, or the Meeting.

Only shareholders of record who hold common shares of the Registrant at the close of business on June 1, 2023, will be entitled to vote at the Meeting and any postponement or adjournments thereof.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-262489, and 333-268690 and 333-269220), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

NLS Pharmaceutics (NASDAQ:NLSP)
Historical Stock Chart
From May 2024 to Jun 2024

NLS Pharmaceutics (NASDAQ:NLSP)
Historical Stock Chart
From Jun 2023 to Jun 2024